These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 22302373)

  • 21. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
    Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
    J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.
    Shaughnessy P; Uberti J; Devine S; Maziarz RT; Vose J; Micallef I; Jacobsen E; McCarty J; Stiff P; Artz A; Ball ED; Berryman R; Dugan M; Joyce R; Hsu FJ; Johns D; McSweeney P
    Bone Marrow Transplant; 2013 Jun; 48(6):777-81. PubMed ID: 23178544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
    Stewart DA; Smith C; MacFarland R; Calandra G
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
    Herbert KE; Demosthenous L; Wiesner G; Link E; Westerman DA; Came N; Ritchie DS; Harrison S; Seymour JF; Prince HM
    Bone Marrow Transplant; 2014 Aug; 49(8):1056-62. PubMed ID: 24887382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
    Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
    Cashen A; Lopez S; Gao F; Calandra G; MacFarland R; Badel K; DiPersio J
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1253-61. PubMed ID: 18940680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
    Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
    Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plerixafor use in patients with previous mobilization failure: A multicenter experience.
    Tekgündüz E; Altuntaş F; Sıvgın S; Akı SZ; Dönmez A; Topçuoğlu P; Yıldırım R; Baysal NA; Ayyıldız E; Yüksel MK; Sarı I; Tombuloğlu M; Unal A; Ilhan O
    Transfus Apher Sci; 2012 Aug; 47(1):77-80. PubMed ID: 22609192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection.
    Cashen AF; Rettig M; Gao F; Smith A; Abboud C; Stockerl-Goldstein K; Vij R; Uy G; Westervelt P; DiPersio J
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1282-1289. PubMed ID: 28476490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly.
    Partanen A; Valtola J; Ropponen A; Vasala K; Penttilä K; Ågren L; Pyörälä M; Nousiainen T; Selander T; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
    Ann Hematol; 2017 Nov; 96(11):1897-1906. PubMed ID: 28879595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
    Maziarz RT; Nademanee AP; Micallef IN; Stiff PJ; Calandra G; Angell J; Dipersio JF; Bolwell BJ
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):670-5. PubMed ID: 23333777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.
    Cheng J; Schmitt M; Wuchter P; Buss EC; Witzens-Harig M; Neben K; Hundemer M; Hillengass J; Alexi R; Goldschmidt H; Chen BA; Ho AD; Schmitt A
    Transfusion; 2015 Feb; 55(2):275-83. PubMed ID: 25117969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Who should be really considered as a poor mobilizer in the plerixafor era?
    Andreola G; Vanazzi A; Radice D; Babic A; Rabascio C; Negri M; Martinelli G; Laszlo D
    Transfus Apher Sci; 2012 Aug; 47(1):27-32. PubMed ID: 22480954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
    Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization.
    Sancho JM; Morgades M; Grifols JR; Juncà J; Guardia R; Vives S; Ferrà C; Batlle M; Ester A; Gallardo D; Millà F; Feliu E; Ribera JM
    Cytotherapy; 2012 Aug; 14(7):823-9. PubMed ID: 22540329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
    Hübel K; Fresen MM; Salwender H; Basara N; Beier R; Theurich S; Christopeit M; Bogner C; Galm O; Hartwig R; Heits F; Lordick F; Rösler W; Wehler D; Zander AR; Albert MH; Dressler S; Ebinger M; Frickhofen N; Hertenstein B; Kiehl M; Liebler S; von Lilienfeld-Toal M; Weidmann E; Weigelt C; Lange F; Kröger N
    Bone Marrow Transplant; 2011 Aug; 46(8):1045-52. PubMed ID: 20972470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.
    Sánchez-Ortega I; Querol S; Encuentra M; Ortega S; Serra A; Sanchez-Villegas JM; Grifols JR; Pujol-Balaguer MM; Pujol-Bosch M; Martí JM; Garcia-Cerecedo T; Barba P; Sancho JM; Esquirol A; Sierra J; Duarte RF
    Bone Marrow Transplant; 2015 Jan; 50(1):34-9. PubMed ID: 25222503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.
    Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E
    Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.